Tumorad is in clinical phase 1, and today, Spago Nanomedical announced that Tumorad had promising results in an orthotopic triple-negative breast cancer model. In our view, this is positive ahead of the further clinical results in 2024. Especially as Tumorad has already produced positive pre-clinical results in colon adenocarcinoma. Our view is that this result will add to the interest in the ongoing clinical Tumorad study.